血液生物标志物鉴别缺血性与出血性卒中
研究纳入发病4.5小时内疑似卒中患者189例(154例缺血性卒中,35例脑出血),检测GFAP、RBP-4、NT-proBNP和内皮抑素。RBP-4+NT-proBNP组合以100%特异性识别29.7%的缺血性卒中;加用高敏GFAP后识别51.5%。纳入62例卒中模拟病后特异性降至98.4%和96.8%。
要点
- RBP-4+NT-proBNP以100%特异性识别29.7%缺血性卒中
- 加用高敏GFAP后以100%特异性识别51.5%缺血性卒中
- 纳入卒中模拟病后特异性分别降至98.4%和96.8%
核心结论
- 包含RBP-4、NT-proBNP和GFAP的生物标志物组合在100%特异性下对缺血性卒中诊断提供中等但可能有用的敏感性。
研究设计与样本
- 研究纳入发病4.5小时内入院的疑似卒中患者,入院时采集血样,用免疫分析法检测GFAP、RBP-4、NT-proBNP和内皮抑素。
- 共纳入189例患者(154例缺血性卒中,35例脑出血),并在另一队列62例卒中模拟病中评估生物标志物组合。
主要发现
- 缺血性卒中患者较脑出血患者RBP-4、NT-proBNP和内皮抑素水平更高,GFAP水平更低。
- RBP-4+NT-proBNP组合以100%特异性识别29.7%的缺血性卒中患者。
- 在高敏GFAP检测亚组中,RBP-4、NT-proBNP和GFAP以100%特异性识别51.5%的缺血性卒中患者。
- 纳入卒中模拟病后,上述特异性分别降至98.4%和96.8%。
- RBP-4和NT-proBNP的即时检测(POCT)结果与传统ELISA相似。
关键数值与推荐
- RBP-4+NT-proBNP组合:100%特异性下识别29.7%缺血性卒中。
- RBP-4+NT-proBNP+高敏GFAP:100%特异性下识别51.5%缺血性卒中。
- 纳入卒中模拟病后特异性分别为98.4%和96.8%。
临床怎么用
- 该生物标志物组合若在未来研究中证实,可能允许对部分患者在院前阶段进行治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate a panel of blood biomarkers to differentiate between ischemic stroke (IS) and intracerebral hemorrhage (ICH) in patients with suspected stroke. METHODS: Patients with suspected stroke admitted within 4.5 hours after onset were enrolled. Blood samples were collected at hospital admission. Glial fibrillary acid protein (GFAP), retinol binding protein 4 (RBP-4), N-terminal proB-type natriuretic peptide (NT-proBNP), and endostatin were measured by immunoassays. Cutoff points were obtained for 100% specificity for IS. A high-sensitivity assay to measure GFAP and rapid point-of-care tests (POCTs) to measure RBP-4 and NT-proBNP were used in subsets of patients. Biomarker panels were evaluated in another cohort of 62 stroke mimics. RESULTS: A total of 189 patients (154 IS and 35 ICH) were enrolled. Patients with IS had higher RBP-4, NT-proBNP, and endostatin and lower GFAP levels than patients with ICH. The best biomarker combination for the identification of IS was RBP-4+NT-proBNP, which was able to identify 29.7% of patients with IS with 100% specificity. In the subset of patients for whom GFAP was measured with the high-sensitivity assay, RBP-4, NT-proBNP, and GFAP identified 51.5% of patients with IS with 100% specificity. When stroke mimics were included, specificities were reduced to 98.4 and 96.8%, respectively. POCTs of RBP-4 and NT-proBNP showed results similar results to those of conventional ELISAs. CONCLUSIONS: A biomarker panel including RBP-4, NT-proBNP, and GFAP provided moderate but potentially useful sensitivity rates at 100% specificity for IS diagnosis. If confirmed in future studies, this strategy might allow prehospital treatment in selected patients. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that a biomarker panel including RBP-4, NT-proBNP, and GFAP distinguishes IS from ICH with moderate accuracy.
引用
- Bustamante A, Penalba A, Orset C, et al. Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes. Neurology. 2021. PMID: 33674361. doi:10.1212/WNL.0000000000011742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。